EMA recommends lifting suspension on aprotinin products
This article was originally published in Scrip
Executive Summary
The European Medicines Agency has recommended that the suspension of the marketing authorisations for aprotinin-containing medicines in the European Union (EU) be lifted - a move that "follows a full review of the benefits and risks of all antifibrinolytic medicines, which found that the results of the BART study on which the suspension was based are unreliable", it said.